Medtronic - AI Stock Analysis

Analysis generated November 25, 2025

Medtronic plc is a global healthcare solutions company committed to improving the health and lives of people around the world. The company provides innovative medical technologies across various disciplines including cardiac and vascular, minimally invasive therapies, restorative therapies, and diabetes. Medtronic operates in more than 150 countries and continues to focus on expanding its product portfolio and global footprint through both organic growth and strategic acquisitions.

Fundamental Analysis

Medtronic reported a revenue of $8.96 billion for the last quarter, marking an increase of 4.46% compared to the previous quarter. Year over year, this represents an increase of 6.64%, indicating positive growth momentum. Notably, net income for the last quarter was $1.37 billion, reflecting a significant growth of 32.12% from the previous quarter and 8.19% year over year. These numbers highlight a robust growth trajectory in terms of profitability.

The company reported an EBITDA of $2.37 billion last quarter, which shows a 6.34% increase over the previous quarter, although there's a decrease of 3.15% compared to the same quarter from the previous year. The current Price to Earnings ratio (P/E) stands at 27.43, which may be regarded as high, potentially signaling overvaluation and a somewhat bearish outlook. Additionally, insider selling activity in the recent months might add to this bearish sentiment.

Technical Analysis

The current stock price stands at $105.35, up by 12.47% from a month ago and showing a year-over-year increase of 26.99%, reflecting a long-term bullish trend. The 10-day Simple Moving Average (SMA10) is $100.48, slightly higher than the previous SMA10 of $99.53, suggesting a potential upward trend in the stock price. The Relative Strength Index (RSI) is at 22.4, which indicates an oversold condition and can be seen as a bullish signal.

Alternative Data Analysis

Medtronic is showing signs of growth and expansion in various dimensions. On the employment front, the company has about 1,305 open positions, up by 31% over the last couple of months, signaling potential future growth. The business outlook among employees remains neutral.

In terms of customer acquisition, Medtronic’s website has approximately 1.9 million visitors, with no significant change in traffic in recent months. However, downloads of its mobile apps are up by 20% to about 200 downloads per day, indicating potential customer growth. On social media, the company has 33,000 Instagram followers, up by 17%, while their Twitter following remains stable at 85,000. Additionally, Medtronic has received an AI score of 61 from AltIndex, which is categorized as a buy signal.

Conclusion and Recommendation

Medtronic displays several positive indications across various metrics. The company is showing steady revenue and profit growth, a stable upward trend in stock price, as well as positive signs in alternative data metrics such as increased job postings and social media engagement. However, the high P/E ratio and recent insider selling activity might be points of concern for potential investors. Overall, the positive growth indicators, coupled with a bullish trend, suggest that Medtronic could be a viable stock for those looking to invest in the healthcare sector. A cautious yet optimistic approach is recommended, aligning with the AltIndex AI score of 61, indicating a buy signal.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.